ABS Direct Equity Fund’s BridgeBio Pharma BBIO Stock Holding History

ABS Direct Equity Fund’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,243	Closed	-$85.8K	–	118
2026 Q1	$85.8K	Buy	+1,243	New	+$90.1K	0.07%	108

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

ABS Direct Equity Fund's BBIO Position: Q2 2026 in Review

ABS Direct Equity Fund sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 1,243 shares — an estimated $85.8K sold.

ABS Direct Equity Fund first reported a position in BBIO in Q1 2026 and held it in 1 quarter. The position peaked at $85.8K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

ABS Direct Equity Fund reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
ABS Direct Equity Fund sold 1,243 BridgeBio Pharma shares in Q2 2026, an estimated $85.8K.
ABS Direct Equity Fund first reported a position in BridgeBio Pharma in Q1 2026 and held it in 1 quarter.
ABS Direct Equity Fund's BridgeBio Pharma position peaked at $85.8K in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on ABS Direct Equity Fund's 13F filing for Q2 2026, filed 13 Aug 2026.